Gracias!
Que casualidad , eh?
Ahi va regalito. Resultados fase II
http://ir.achillion.com/releaseDetail.cfm?ReleaseID=731671
ACHN
Edito:
"ACH-3102 has been well-tolerated by all patients with no serious adverse events, subject withdrawals, or on-treatment viral breakthrough reported to date. Treatment with ACH-3102 has resulted in rapid reduction in HCV RNA accompanied by normalization of liver enzymes.
"We are very pleased to see that the profile of ACH-3102 continues to EXCEED OUR EXPECTATIONS for providing a truly improved barrier to resistance. As the first-ever clinical trial to evaluate a NS5A inhibitor as a single direct-acting antiviral in combination with ribavirin, we are extremely encouraged by these initial results that demonstrate rapid suppression of the HCV GT1b virus and a well-tolerated safety profile through 12 weeks of therapy,"